4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock.

A number of other research analysts have also weighed in on the stock. Morgan Stanley assumed coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an “underweight” rating and a $8.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, Leerink Partners reissued an “outperform” rating and issued a $36.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Trading Down 13.8 %

Shares of 4D Molecular Therapeutics stock opened at $4.76 on Monday. The firm has a market capitalization of $220.05 million, a PE ratio of -1.67 and a beta of 2.81. 4D Molecular Therapeutics has a twelve month low of $4.68 and a twelve month high of $36.25. The firm’s 50-day moving average price is $6.94 and its 200 day moving average price is $11.88.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $40,000. Values First Advisors Inc. purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. increased its holdings in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after purchasing an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at approximately $108,000. Finally, Quest Partners LLC increased its holdings in 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after purchasing an additional 5,745 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.